Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
FedEx, UPS And Some Other Big Stocks Moving Lower In Today’s Pre-Market Session
U.S. stock futures traded lower this morning after recording losses in the previous session. Here are some big stocks recording losses in today’s pre-market trading session.
Kroger, DocuSign And Other Big Gainers From Friday
U.S. stocks closed higher with the Nasdaq Composite surging 250 points on Friday. Here is the list of some big stocks recording gains in the previous session.
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
Gainers
Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash.
Piper Sandler Maintains Neutral on Bausch Health Companies, Lowers Price Target to $6
Piper Sandler analyst David Amsellem maintains Bausch Health Companies (NYSE:BHC) with a Neutral and lowers the price target from $7 to $6.
Expert Ratings for Bausch Health Companies
Bausch Health Companies (NYSE:BHC) has observed the following analyst ratings within the last quarter:
Why Express Is Trading Higher By Over 21%, Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Nuwellis, Inc. (NASDAQ: NUWE) shares jumped 140% to $1.5894 after the company announced new clinical data demonstrating 100% survival at 30 days following the use of ultrafiltration in high-risk postoperative coronary artery bypass grafting patients.
‘Bausch Health Hires Advisers Amid Patent Loss, Spinoff Controversy’ -Wall Street Journal
https://www.wsj.com/articles/bausch-health-hires-advisers-amid-patent-loss-spinoff-controversy-11661201254
Bausch Health Continuing Process Toward Separating Bausch + Lomb
Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") has transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb